Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

4scar-cd22/cd123/cd38/cd10/cd20/tslpr

Preclinical

SShenzhen Geno-Immune Medical Institute

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[2][1]

Indication

B-Cell LeukemiaNot yet recruiting

B-Cell LeukemiaPreclinical

Not yet recruiting

Timeline

Expected Milestones

Q2 2029

PreclinicalNot yet recruiting

B-Cell Leukemia

NCT04016129

Clinical

Trials by Indication[1]

B-Cell Leukemia1 trial

CART Immunotherapy Targeting CD19 Negative Acute Lymphoblastic Leukemia

Not yet recruiting·SShenzhen Geno-Immune Medical Institute·Preclinical·NCT04016129·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for 4scar-cd22/cd123/cd38/cd10/cd20/tslpr. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for 4scar-cd22/cd123/cd38/cd10/cd20/tslpr. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Shenzhen Geno-Immune Medical Institute company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Preclinical[1]
Company: SShenzhen Geno-Immune Medical Institute

Related News